A 2025 analysis from Komodo Health found that Anthem denied 38% of initial PA requests for Wegovy and 33% for Zepbound
Start here 1
Ongoing Monitoring: If Semaglutide treatment is initiated, we will provide regular follow-up appointments to monitor your progress, adjust the dosage if necessary, and address any concerns or side effects
Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical
Higher doses and longer treatment durations may be necessary to achieve therapeutic glutathione levels
Keep a Log: Use a simple calendar or a health app to check off when you have taken your dose